ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 95 for:    Recruiting, Not yet recruiting, Available Studies | "Muscular Dystrophies"
Previous Study | Return to List | Next Study

Stem Cell Therapy in Muscular Dystrophy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02241928
Recruitment Status : Recruiting
First Posted : September 16, 2014
Last Update Posted : March 29, 2018
Sponsor:
Information provided by (Responsible Party):
Neurogen Brain and Spine Institute

September 12, 2014
September 16, 2014
March 29, 2018
January 2009
December 2018   (Final data collection date for primary outcome measure)
Manual Muscle Testing [ Time Frame: 1 year ]
Same as current
Complete list of historical versions of study NCT02241928 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Stem Cell Therapy in Muscular Dystrophy
Role of Autologous Mononuclear Cell Therapy in Muscular Dystrophy
The purpose of this study was to analyze the effect of autologous bone marrow mononuclear cells in muscular dystrophy.
Not Provided
Interventional
Phase 1
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Muscular Dystrophy
Biological: Stem Cell
Intrathecal Autologous bone marrow mononuclear cell transplantation
Experimental: Stem Cell
Bone marrow mononuclear cell transplantation
Intervention: Biological: Stem Cell
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
1000
Same as current
May 2019
December 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • age group of 6 months and above
  • muscular dystrophy diagnosed on the basis of clinical presentation

Exclusion Criteria:

  • presence of respiratory distress
  • presence of acute infections such as Human Immunodeficient Virus/Hepatitis B Virus/Hepatitis C Virus
  • malignancies
  • acute medical conditions such as respiratory infection, fever, hemoglobin less than 8, bleeding tendency, bone marrow disorder, left ventricular ejection fraction < 30%
  • pregnancy or breastfeeding
Sexes Eligible for Study: All
6 Months to 60 Years   (Child, Adult)
No
Contact: Alok K Sharma, M.S, M.Ch 022-25283706 alok276@gmail.com
India
 
 
NCT02241928
NGBSI-14
Yes
Not Provided
Not Provided
Neurogen Brain and Spine Institute
Neurogen Brain and Spine Institute
Not Provided
Not Provided
Neurogen Brain and Spine Institute
March 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP